14 May 2024
14 May 2024
The investment will create more than 500 jobs and enhance medicine production capabilities in the region.
Highly potent active pharmaceutical ingredients (HPAPIs) are essential for chemotherapies and combination therapies. With specialised production facilities in great demand, what are the key challenges in HPAPI manufacturing?
Fulcrum entered an exclusive global license deal with GSK for rights to the oral small-molecule drug losmapimod in April 2019.
Naloxone is known for its rapid action in reversing opioid overdose effects, particularly breathing difficulties.
Regeneron and Sanofi’s injection saw sales of $11.59bn in 2023 as it gets a step closer to another indication.
The approval was supported by the TRIDENT-1 trial studying Augtyro in TKI-naïve and TKI-pretreated patients with ROS1-positive NSCLC.
A 41% decline in mortality risk in patients treated with tafamidis versus placebo was reported in clinical trials.
Takeda will pay $100m upfront and up to $2.1bn in milestone-based payments for licensing AC immune’s amyloid beta-targeting immunotherapy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
